**Program - Icthic April 8-10, 2016**

**Friday April 8th 2016**

9,00 - 11,00 am  **Industry sponsored session**

11,00 - 11,15 am  **Congress Opening: A Falanga, FR Rickles, B Brenner**

11,15 - 1,30 pm  **Plenary Session 1: Epidemiology of thrombosis in cancer**  
*Chairs: N Key (USA); TBA*

**PL01:**  **Venous thromboembolism and occult cancer: impact on clinical practice**  
M Carrier (Canada)

**PL02:**  **Cancer associated thrombosis: risk factors and outcomes**  
S Eichinger (Austria)

**PL03:**  **Update of incidental VTE in cancer**  
H Liebman (USA)

**PL04:**  **Thrombosis and anticancer therapies: the contribution of chemotherapy and the specific drugs implicated in CAT**  
P Mismetti (France)

**Oral Communications**

1,30 - 2,30 pm  **Lunch/Lunch session**
2,30 - 4,45 pm  **Plenary Session 2: Role of hemostatic pathways in cancer progression - searching for better molecular targets for therapy**

*Chairs: TBA*

**PL05:**  **Microparticles and cancer thrombosis in animal models**
Christophe Dubois (France)

**PL06:** **Inhibition of platelet function as a target for cancer progression control**
J Italiano (USA)

**PL07:** **Biological basis of personalised anticoagulation in cancer: oncomir networks as regulators of coagulopathy**
J Rak (Canada)

**PL08:** **Heparanase procoagulant activity in cancer progression**
Y Nadir (Israel)

**Oral Communications**

4,45 - 5,15 pm  **Coffee Break**
5,15 - 7,30 pm  **Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer**
*Chairs:* B Brenner (Israel); S Kostantinides (Germany)

**PL09**  
**Cancer-associated thrombosis novel biomarker discovery**  
N Kuderer (USA)

**PL10**  
**VTE risk assessment models in cancer**  
I Pabinger (Austria)

**PL11**  
**Polymorphisms of clotting factors and cancer risk**  
P Sandset (Sweden)

**PL12**  
**The HYPERCAN prospective study**  
A Falanga (Italy)

**Oral Communications**

7,30 pm  **Plenary Lecture: 4th Simon Karpatkin Memorial Lecture**

*Chairs:* A Falanga (Italy); B Brenner (Israel); FR Rickles (USA)

**Introduction to Lecture**  
FR Rickles (USA)

**SKML**  
**Targeting clotting proteins in cancer therapy - progress and challenges**  
W Ruf (USA; Germany)
Saturday April 9th 2016

8,30 - 10,45 am  **Plenary Session 4: Hematological malignancies and hemostatic complications**
*Chairs: TBA*

**PL13**  Intracranial hemorrhage in cancer patients on anticoagulation
J Zwicker (USA)

**PL14**  Management of cancer-associated disseminated intravascular coagulation
M Levi (The Netherlands)

**PL15**  New insights into the biology and management of thrombosis in myeloproliferative neoplasms
T Barbui (Italy)

**PL16**  Update of thrombosis in multiple myeloma
FW Leebeek (The Netherlands)

**Oral Communications**

10,45 - 11,15 am  **Coffee Break**
11,15 am - 1,30 pm  Plenary Session 5: Risk factors for thrombosis in cancer
Chairs: I Elalamy (France); GM Liumbruno (Italy)

PL17  Upper extremity deep vein thrombosis: comparison between cancer and non-cancer patients
SM Bleker (The Netherlands)

PL18  Risk of thrombosis and supportive care (transfusion, catheters, growth factors)
G Castaman (Italy)

PL19  New findings from global registries of cancer-associated thrombosis
AK Kakkar (UK)

PL20  Predictors of recurrent VTE and bleeding on anticoagulation
AA Khorana (USA)

Oral Communications

1,30 - 2,30 pm  Lunch / Lunch Session

2,30 - 3,00 pm  Special Session
Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel)

SPL  History of ICTHIC - How has the field progressed since our first meeting in 2001?
FR Rickles (USA)

3,00 - 4,30 pm  Poster sessions with refreshments
Poster walk discussion sessions with chair
4,30 - 6,45 pm  **Plenary Session 6: Prophylaxis of thrombosis in cancer patients**

*Chairs: TBA*

**PL21**  
*Primary prophylaxis of VTE in cancer outpatients*  
D Imberti (Italy)

**PL122**  
*Thromboprophylaxis in hospitalized Cancer Patients: a comparison of guidelines*  
M Levine (USA)

**PL23**  
*Long term cardiovascular complications of chemotherapy in patients with cancer*  
PW Kamphuisen (The Netherlands)

**PL24**  
*DOACs in cancer patients - what is known and what are the active trials*  
G Agnelli (Italy)

**Oral Communications**
Sunday April 10th 2016

8,30 - 10,45 am  Plenary Session 7: Treatment of cancer-associated thrombosis
Chairs: H ten Cate (The Netherlands); G Lyman (USA)

PL25  CAT treatment: guidelines update
AYY Lee (Canada)

PL26  Management of recurrent venous thromboembolism in cancer patients
W Ageno (Italy)

PL27  The use of inferior vena cava filters in patients with cancer
T Wun (USA)

PL28  Management of bleeding complications in cancer patients on DOACs
S Schulman (Canada)

Oral Communications

10,45 - 11,15 am  Coffee Break
11,15 am - 1,30 pm  **Plenary session 8: Open questions in cancer and thrombosis**
Chairs: H Buller (The Netherlands); TBA

**PL29**  Anticoagulant and cancer: Will overall survival increase?  
HH Versteeg (The Netherlands)

**PL30**  Does one size fit all? Who should get LMWH/warfarin/DOACs?  
S Noble (UK)

**PL31**  LMWH in cancer patients with renal impairment - better than warfarin?  
R Bauersachs (Germany)

**PL32**  Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients  
J Harenberg (Germany)

--

**Oral Communications**

1,30 - 1,45 pm  **Concluding Remarks**